Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva

Sponsor
Lund University Hospital
Study ID
NCT00598156
Phase
PHASE3
Status
Completed

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Chemotherapy and bevacizumab is given for 4 months. Patients who have not progressed will continue with maintenance treatment with either bevacizumab (Avastin) alone, or bevacizumab and erlotinib (Tarceva).

Key Dates

First listed
Jan 18, 2008
Start date
Jun 30, 2007
Status verified
Apr 2013
Primary completion
Oct 31, 2009
Completion
Aug 31, 2012

Study Design

Enrollment
249 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab and erlotinib as maintenance treatment until progression
  • Experimental: 2
    bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab every third week until progression

Primary Outcome Measure

progression-free survival [ Time Frame: 3 years ]

Related Studies